IRVINE, Calif., June 28, 2022 (GLOBE NEWSWIRE) — JenaValve Technology, Inc. (“JenaValve” or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, announced positive results from the first Trilogy Heart Valve System commercial implants for high-surgical risk patients with severe, symptomatic aortic stenosis (AS) or aortic […]
Tag: Trilogy Heart Valve System
JenaValve Announces First European Commercial Implants with the Trilogy™ Heart Valve System
IRVINE, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the first commercial implants with the Trilogy Heart Valve System in Europe. The procedures, which included treatment of both aortic regurgitation1 (AR) and aortic stenosis1 (AS), took place […]
JenaValve Receives IDE Approval to Initiate The ALIGN-AR Pivotal PMA Trial
IRVINE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced FDA approval for the company to initiate its Investigational Device Exemption (IDE) PMA clinical trial for the Trilogy™ Heart Valve System for severe symptomatic, high-surgical risk […]
Recent
Transverse Medical Inc. Announces Completion of First Series of Patients in Feasibility Clinical Study at Victorian Heart Hospital, Melbourne, Australia, Using Point-Guard Cerebral Embolic Protection.
The Future of AI & Electrophysiology Takes Center Stage at Heart Rhythm 2025 with Vektor Medical
CathVision to Exhibit the Latest Advancements in Electrophysiology at Heart Rhythm Society 2025 in San Diego
Popular
- No commented posts yet